Lupin signs distribution agreement with Medis for orphan drug NaMuscla 

The agreement enables expanded patient access of the only EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders in Central and Eastern European territories

Lupin yesterday entered into a distribution agreement with Medis for Lupin’s orphan drug NaMuscla (mexiletine). Medis will commercialise NaMuscla for the symptomatic treatment of myotonia in adults with Non-Dystrophic Myotonic (NDM) disorders in Central and Eastern European countries. NaMuscla is the first and only licensed product for this indication, Lupin said in a statement.

Under the agreement, Medis will initially focus on the commercialisation of NaMuscla in the Central and East European countries, namely Croatia, Czech Republic, Hungary, Slovakia and Slovenia in the first phase. Lupin will continue commercialisation of NaMuscla in Germany, France and the UK, the statement notified.

The statement also mentioned that NDM disorders are a group of rare and inherited neuromuscular disorders which is characterised by the inability to relax muscles following voluntary contraction. NaMuscla reduces myotonia symptoms in people with NDM, resulting in a significant improvement in quality of life and other functional and clinical outcomes for patients. NaMuscla, which has been designated orphan drug status, received the EU marketing authorisation in December 2018.

LupinMedisNaMusclaOrphan Drug
Comments (0)
Add Comment